Financiere de Tubize SA
FTD
Company Profile
Business description
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Contact
Allee de la Recherche, 60
Brussels1070
BELT: +32 497515208
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
250
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
stocks
What next for Nine Entertainment after Domain payout?
The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.70 | 18.10 | 0.20% |
| CAC 40 | 7,825.24 | 1.72 | 0.02% |
| DAX 40 | 23,698.15 | 5.50 | -0.02% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.29 | 14.29 | -0.15% |
| HKSE | 26,388.16 | 301.84 | 1.16% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,227.90 | 1.25 | -0.01% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,864.90 | 22.00 | 0.25% |
| SSE Composite Index | 3,870.60 | 4.71 | -0.12% |